Rispoval 2 / BRSV + Pi3
Active substance
ATC code
Species
Cattle
Indications
Active immunisation of cattle from 12 weeks of age to:
- reduce virus excretion caused by bovine Pi3 virus and
- reduce virus excretion caused by BRSV infection.
| Onset of immunity: | 3 weeks after the basic vaccination scheme |
| Duration of immunity: | 6 months after the basic vaccination scheme for BRSV. Duration of immunity has not been established for bovine Pi3 virus. |
Dose to be administered and administration route
Reconstitute the vaccine by adding the solvent to the vial containing the lyophilisate.
When the lyophilisate and solvent are filled in equally sized vials, inject the entire solvent into the vial containing the lyophilisate.
When the lyophilisate is filled in a smaller vial size than the solvent, the reconstitution of the vaccine is carried out in 2 steps:
1.Inject 10ml of the solvent on the lyophilised plug in the vial containing the lyophilisate.
2.Shake well and extract the reconstituted lyophilised fraction from the vial and mix with the remaining solvent in the liquid fraction vial.
Shake well before use.
Reconstituted product: pink-orange turbid suspension with loose sediment.
Dose: 4 ml
Route: Intramuscular use
Vaccination scheme:
Basic vaccination: Two doses of Rispoval 2, 3-4 weeks apart from 12 weeks of age.
Re-vaccination: If continued protection against BRSV is required, then animals should be revaccinated after 6 months. The duration of immunity of the Pi3 component is not known.
Animals should preferably be vaccinated at least 3 weeks before a period of stress or high infection risk such as re-grouping or transport of animals, or the start of autumn season.
Adverse reactions
Transient and mild hyperthermia which can last for 2 days and a transient, minor local inflammation reaction of up to 0.5 cm which disappears within 15 days can occur very commonly after administration of the vaccine. Very rarely, the vaccine may cause hypersensitivity reactions. In case of anaphylactic reaction, symptomatic treatment should be provided.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
